Cirrhosis and chronic liver failure

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 97-137

  Hardy, Stephen ^a,b   Kleinman, Ronald E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927978769     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.008     Document Type: Chapter

References (427)

1. Anthony PP, Ishak KG, Nayak NC. Themorphology of cirrhosis: definition, nomenclature, and classification. Bull WHO 1977; 55:521–40.
2. Ruben E, Krus S, Popper H. Pathogenesis of postnecrotic cirrhosis in alcoholics. Arch Pathol 1962;73:288–99.
3. Fauerholdt L, Schlichting P, Christensen E, et al. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology 1983;3:928–31.
4. Poppor H, Berk PD. Lessons from the study of cirrhosis and other fibrotic disease of the liver. In: Berk PD, Wasserman LR, eds. Myelofibrosis and the biology of connective tissue. New York: Alan R. Liss, 1984:405–24.
5. Popper H, Schaffner F. Chronic hepatitis: taxonomic, etiologic and therapeutic problems. In: Schaffner F, Popper H, eds. Progress in liver disease. Vol. 5. New York: Grune and Stratton, 1976:535.
6. Silverman A, Roy CC. Chronic active hepatitis. In: Roy CC, Silverman A, eds. Pediatric clinical gastroenterology. St. Louis: Mosby, 1983.
7. Maddrey WL, Boitnott JK. Drug induced chronic liver disease. Gastroenterology 1977;72:1348–53.
8. Geoffrey L. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987;252:1–9.
9. Martin GR, Kleinman HK. The extracellular matrix component in development and disease. Semin Liver Dis 1985;5:147–56.
10. Biagini G, Ballardini G. Liver fibrosis and extracellular matrix. J Hepatol 1989;8:115–24.
11. Hascall V. Proteoglycans: structure and function. In: Ginsberg V, ed. Biology of carbohydrates. New York: John Wiley & Sons, 1981:1–49.
12. Hynes R. Molecular biology of fibronectin. Annu Rev Cell Biol 1985;1:67–90.
13. Clark R. Potential roles of fibronectin in cutaneous wound repair. Arch Dermatol 1987;3:57–85.
14. Bitterman PB, Wewers MD, Rennard SI, et al. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest 1986;77:700–8.
15. Aumanailley M, Nurcombe V, Edgar D, et al. The cellular interactions of laminin fragments: cell adhesion correlations with two fragment-specific high affinity binding sites. J Biol Chem 1987;262:11532–8.
16. Martin GR, Timpl R. Laminin and other basement membrane components. Annu Rev Cell Biol 1987;3:57–85.
17. Bissell DM, Stamatoglou SC, Nermut MV, et al. Interactions of rat hepatocytes with type IV collagen, fibronectin and laminin matrices: distinct matrix-controlled models of attachment and spreading. Eur J Cell Biol 1986;40:72–8.
18. Hahn EG, Schuppan D. Ethanol and fibrogenesis in the liver. In: Seitz HK, Kommerell B, eds. Alcohol related disease in gastroenterology. Berlin: Springer Verlag, 1985:124–53.
19. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin and fibronectin. Gut 1980;21:63–71.
20. Preaux AM, Mallat A, Van Nhieu JT, et al. Matrix metalloproteinase- 2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999;30:944–50.
21. Blaheta RA, Kronenberger B, Woitaschek D, et al. Dedifferentiation of human hepatocytes by extracellular matrix proteins in vitro: quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments. J Hepatol 1998;28: 677–90.
22. Bianchi FB, Biagini G, Ballardini G, et al. Basement membrane production by hepatocytes in chronic liver disease. Hepatology 1984;4:1167–72.
23. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963;44:239–42.
24. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122:1525–8.
25. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795–808.
26. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33–42.
27. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647–54.
28. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5.
29. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
30. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
31. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991;24:219–39.
32. Niernela O, Risteli J, Blake JE, et al. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease: relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990;98:1612–19.
33. Schneider M, Voss B, Hogemann B, et al. Evaluation of serum laminin pl, procollagen-III peptides, and n-acetyl-Bglucosaminidase for monitoring the activity of liver fibrosis. Hepatogasteroenterology 1989;36:506–10.
34. Gressner AM, Tittor W, Negwer A, et al. Serum concentrations of laminin and propeptide of type III collagen in relation to the portal venous pressure of fibrotic liver disease. Clin Chem Acta 1986;161:249–58.
35. Gressner AM, Tittor W, Negwer A. Serum concentrations of N-terminal propeptide of type III procollagen and laminin in the outflow of fibrotic livers. Hepatogasteroenterology 1986;33: 191–5.
36. Bahr MJ, Boker KH, Horn W, et al. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis. Hepatogasteroenterology 1997;44:1200–5.
37. Korner T, Kropf J, Gressner AM. Serumlaminin andhyaluronan in liver cirrhosis: markers of progression with high prognastic value. J Hepatol 1996;25:684–8.
38. Murawaki Y, Kusakabe Y, Hirayama C. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology 1991;14: 1167–73.
39. Misaki M, Shima T, Yano Y, et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin Chem 1990;36:522–4.
40. Ji X, Li S, Kong X, et al. Clinical significance of serum7s collagen and type VI collagen levels for the diagnosis of hepatic fibrosis. Chin Med J (Engl) 1997;110:198–201.
41. Babbs C, Smith A, Hunt LP, et al. Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1988;1:1021–4.
42. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113: 1609–16.
43. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544–53.
44. Saile B, Matthes N, Knittel T, et al. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 1999;30:196–202.
45. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999;14:618–33.
46. Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 2004;6:60–5.
47. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003;37:336–9.
48. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2: 148–55.
49. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222–5.
50. Rimola A, Londono MC, Guevara G, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78: 686–91.
51. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304–11.
52. Fausto N, Mead J. Regulation of liver growth: protooncogenes and transforming growth factors. Lab Invest 1989;60:4–13.
53. Smuckler EA, James JL. Irreversible cell injury [abstract]. Pharmacol Rev 1984;36:77S–91S.
54. Higgins GM, Anderson RM. Experimental pathology of the liver: 1. Restoration of the liver of the white rat following surgical removal. Arch Pathol 1931;12:186–202.
55. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991;13:364–75.
56. Waterfield M. Epidermal growth factors and related molecules. Lancet 1989;1:1243–6.
57. Skov-Olsen P, Boesby S, Kirkegaard P, et al. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in rats. Hepatology 1988;8:992–6.
58. Ekberg S, Carlsson L, Carlsson B, et al. Plasma growth hormone pattern regulates epidermal growth factor (EGF) receptor messenger ribonucleic acid levels and EGF binding in the rat liver. Endocrinology 1989;125:2158–66.
59. Francavilla A, Ove P, Polimeno L, et al. Different response to epidermal growth factor of hepatocytes in cultures isolated from male or female rat liver: inhibitor effect of estrogen on binding and mitogenic effect of epidermal growth factor. Gastroenterology 1987;93:597–605.
60. Napoli J, Prentice D, Niinami C, et al. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated ratmodel of cirrhosis. Hepatology 1997;26:624–33.
61. Hashimoto M, Kothary PC, Eckhauser FE, Raper SE. Treatment of cirrhotic rats with epidermal growth factor and insulin accelerates liver DNA synthesis after partial hepatectomy. J Gastroenterol Hepatol 1998;13:1259–65.
62. Nakayama H, Tsubouchi H, Gohda E, et al. Stimulation of DNA synthesis in adult rat hepatocytes in primary culture by sera from patients with fulminant hepatic failure. Biomed Res 1985;6:231–7.
63. Tsubouchi H, Hirono S, Gohda E, et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 1989;9:875–81.
64. Gohda E, Tsubouchi H, Nakayama H, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988; 81:414–19.
65. Tashiro K, Hagiya M, Nishizawa T, et al. Deduced primary structure of rat hepotocyte growth factor and expression of the m RNA in rat tissue. Proc Natl Acad Sci U S A 1990;87: 3200–4.
66. Gohda E, Hayashi Y, Kawaida A, et al. Hepatotrophic factor in blood of mice treated with carbon tetrachloride. Life Sci 1990;46:1801–8.
67. Tsubouchi H, Hirono S, Gohda E, et al. Human hepatocyte growth factor in blood of patients with fulminant hepatic failure: I. Clinical aspects. Dig Dis Sci 1991;36:780–4.
68. Shimizu I, Ichihara A, Nakamura T. Hepatocyte growth factor in ascites from patients with cirrhosis. J Biochem (Tokyo) 1991;109:14–18.
69. Gauldie J, Richards C, Harnish D, et al. Interferon beta2/Bcell stimulatory factor type 2 shares identity with monocytederived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251–5.
70. Mead JE, Fausto N. Transforming growth factor a may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci U S A 1989;86: 1558–62.
71. Castilla A, Prieto J, Fausto N. Transforming growth factors B1 and a in a chronic liver disease: effects of interferon alpha therapy. N Engl J Med 1991;324:933–40.
72. Brenner DA, Koch KS, Leffert HL. Transforming growth factor alpha stimulates proto-oncogene cejun expression and a mitogenic program in primary cultures of adult rat hepatocytes. DNA 1989;8:279–85.
73. Harada K, Shiota G, Kawasaki H. Transforming growth factoralpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19:318–25.
74. Wollenberg GK, Semple E, Quinn BA, Hayes MA. Inhibition of proliferation of normal preneoplastic and neoplastic rat hepatocytes by transforming growth factor-beta. Cancer Res 1987;46:6595–9.
75. Nakatsukasa H, Evarts RP, Hsia CC, et al. Transforming growth factor-beta 1 and type 1 procollagen transcripts during regeneration and early fibrosis of rat liver. Lab Invest 1990;63: 171–80.
76. Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforminggrowth factor-beta 1 in fibrotic liver diseases. Hepatology 1991;14:269–73.
77. Czaja M, Weiner FR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 1989;108:2477–82.
78. Armendariz-Borunda J, Seyer JM, Kang AH, et al. Regulation of TGF beta gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J 1990;4:215–21.
79. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986;83:4167–71.
80. Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGFbeta in hepatic fibrosis. Front Biosci 2002;7:d793–807.
81. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47–64.
82. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989;58: 575–606.
83. Presta M, Statuto M, Rusnati M, et al. Characterization of a Mr 25, 000 basic fibroblast growth factor form in adult, regenerating, and fetal rat liver. Biochem Biophys Res Commun 1989;164:1182–9.
84. Ikebuchi K, Wong GG, Clark SC, et al. Interleukin-6 enhancement of interleukin-3 dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A 1987;84:9035–9.
85. Sharon N, Bird G, Goka J, et al. Elevated plasma IL-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991;84:449–53.
86. West MA, Billiar TR, Curran RD, et al. Evidence that rat Kupffer cells stimulate and inhibit hepatocyte protein synthesis in vitro by differentmechanisms. Gastroenterology 1989;96:1572–82.
87. Goss J, Mangino MJ, Flye MW. Prostaglandin E2 production during hepatic regeneration downregulates Kupffer cell IL-6 production. Ann Surg 1992;215:253–60.
88. Hayakawa T, Kondo T, Shibata T, et al. Serum insulin-like growth factor II in chronic liver disease. Dig Dis Sci 1989;34: 338–42.
89. Wu JC, Daughaday WH, Lee SD, et al. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988;112:589–94.
90. Assy N, Hochberg Z, Amit T, et al. Growth hormone-stimulated insulin-like growth factor I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997;27:796–802.
91. Caufriez A, Reding P, Urbain D, et al. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991;14:317–21.
92. Shaarawy M, Fikry MA, Massoud BA, Lotfy S. Insulin-like growth factor binding protein-3: a novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab 1998;83:3316–19.
93. Sherlock S. Diseases of the liver and biliary system. Boston: Blackwell, 1985:339.
94. Haellen J, Norden J. Liver cirrhosis unsuspected during life. A series of 79 cases. J Chronic Dis 1964;17:951–8.
95. Attali P, Ink O, Pelletier G, et al. Dupuytren’s contracture, alcohol consumption, and chronic liver disease. Arch Intern Med 1987;147:1065–7.
96. Phillips MM, Ramsey GR, Conn HO. Portacaval an anastomosis and peptic ulcer: a nonassociation. Gastroenterology 1975;68:121–31.
97. Bouchier I. Postmortem study of the frequency of gallstones in patients with cirrhosis of the liver. Gut 1969;10:705–10.
98. Nicholas P, Rinaudo PA, Conn HO. Increased incidence of cholelithiasis in Laénnec’s cirrhosis. Gastroenterology 1972;63: 112–21.
99. Vlahcevic ZR, Yoshida T, Juttijudata P, et al. Bile acid metabolism in cirrhosis: III. Biliary lipid secretion in patients with cirrhosis and its relevance to gallstone formation. Gastroenterology 1973;64:298–303.
100. Keren G, Boichis H, Zwas TS, Frand M. Pulmonary arteriovenous fistulae in hepatic cirrhosis. Arch Dis Child 1983;58: 302–4.
101. Hall GH, Laidlaw CD. Further experimental evidence implicating reduced ferritin as a cause of digital clubbing. Clin Sci 1963;24:121–6.
102. Tobin CE, Zariquiey MO. Arteriovenous shunts in the human lung. Proc Soc Exp Biol Med 1950;75:827–9.
103. Sheehy TW, Berman A. The anemia of cirrhosis. J Lab Clin Med 1960;56:72–82.
104. Roberts HR, Cederbaum AI. The liver and blood coagulation: physiology and pathology. Gastroenterology 1972;63: 297–320.
105. Pirovino M, Linder R, Boss C, et al. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr 1988;66:298–302.
106. Erlinger S, Bircher J. Cirrhosis: clinical aspects. In: Bircher J, Mcintyre N, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1991:380.
107. Fitzpatrick T, Johnson R, Polano M. Color atlas and synopsis of clinical dermatology: common and serious diseases. 2nd ed. New York: Mc Graw Hill, 1994.
108. Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol 1972;57:431–7.
109. Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis 1985;5: 35–45.
110. Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45:301–13.
111. Burack WR, Hollister RM. Tuberculous peritonitis: a study of forty-sevenproved cases encountered by a general medical unity in twenty-five years. Am J Med 1960;28:510–23.
112. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53–8.
113. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing, and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252–62.
114. Hassner A, Kletter Y, Shlag D, et al. Impairedmonocyte function in liver cirrhosis. Br J Med 1981;282:1262–3.
115. Wyke RJ, Rajkovic IA, Williams R. Impaired opsonization by serum from patients with chronic liver disease. Clin Exp Immunol 1983;51:91–8.
116. Yousif-Kadaru AG, Rajkovic IA, Wyke RJ, et al. Defects in serum attractant activity in different types of chronic liver diseases. Gut 1984;25:79–84.
117. Kourilsky O, Leroy C, Peltier AP. Complement and liver cell function in 53 patients with liver disease. Am J Med 1973;55: 574–678.
118. Fox RA, Dudley FJ, Sherlock S. The serum concentration of the third component of complement beta-1C-beta-1A in liver disease. Gut 1971;12:574–8.
119. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973;14:451–6.
120. Deviere J, Denys C, Schandene L, et al. Decreased proliferation activity associated with activation markers in patients with alcoholic liver cirrhosis. Clin Exp Immunol 1988;72:377–82.
121. Rutenburg AM, Sonnenblick E, Koven I, et al. Comparative response of normal and cirrhotic rats to intravenously injected bacteria. Proc Soc Exp Biol 1959;101:279–81.
122. Kerr DN, Pearson DT, Read AE. Infection of the ascitic fluid in patients with cirrhosis. Gut 1963;4:394–8.
123. Sokol R. Medicalmanagementof the infant or childwith chronic liver disease. Semin Liver Dis 1987;7:166–7.
124. Sokol RJ, Stall C. Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990;52:203–8.
125. Chin SE, Shepherd RW, Thomas BJ, et al. The nature of malnutrition in children with end-stage liver disease awaiting orthotopic liver transplantation. Am J Clin Nutr 1992;56:164–8.
126. Kaufman SS, Murray ND, Wood RP, et al. Nutritional support for the infant with extrahepatic biliary atresia. J Pediatr 1987;110:679–86.
127. Reichling JJ, Kaplan MM. Clinical use of serumenzymes in liver disease. Dig Dis Sci 1988;33:1601–14.
128. St Louis P. Biochemical studies: liver and intestine. In: Walker WA, Durie PR, Hamilton JR, et al., eds. Pediatric gastroenterology and nutrition. Philadelphia: BC Decker, 1991;1363–73.
129. Kaplan M. Alkaline phosphatase. Gastroenterology 1972;62: 452–68.
130. Astin T. Systemic reaction to bromsulphthalein. Br Med J 1965; 2:1433.
131. Balistreri WF, Setchell K. Newer liver function tests. Front Gastro Res 1989;16:220–45.
132. Schoeller DA, Schneider JF, Solomons NW, et al. Clinical diagnosis with the stable isotope 13C in CO2 breath tests: methodology and fundamental considerations. J Lab Clin Med 1977;90: 412–21.
133. Schneider JF, Baker AL, Haines NW, et al. Aminopyrine Ndemethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980;79:1145–50.
134. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984;4: 38–46.
135. Jost G, Wahllander A, von Mandach U, et al. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987;7:338–44.
136. Post J, Patek A. Serum proteins in cirrhosis of the liver. Arch Intern Med 1942;169:67–82.
137. Hasch E, Jarnum S, Tygstrup N. Albumin synthesis rate as a measure of liver function in patients with cirrhosis. Acta Med Scand 1967;182:83–92.
138. Rothschild MA, Oratz M, Zimmon D, et al. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate 14-C. J Clin Invest 1969;48:344–50.
139. Haider M, Haider SQ. Assessment of protein-calorie malnutrition. Clin Chem 1984;30:1286–99.
140. Dymock IW, Tucker JS, Woolf IL, et al. Coagulation studies as a prognostic index in acute liver failure. Br J Haematol 1975; 29:385–95.
141. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6:648–51.
142. Biland L, Duckert F, Prisender S, et al. Qualitative estimation of coagulation factors in liver disease: the diagnostic and prognostic value of factor XIII, factor V, and plasminogens. Thromb Haemost 1978;39:646–56.
143. Schlichting P, Christensen E, Andersen PK, et al. Prognostic factors in cirrhosis identified by Cox’s regression model. Hepatology 1983;6:889–95.
144. Malatack JJ, Schaid DJ, Urbach AH. Choosing a pediatric recipient I-or orthotopic liver transplantation. J Pediatr 1987; 111:479–89.
145. Starling E. On the absorption of fluids from the connective tissue spaces. J Physiol (Lond) 1896;19:312.
146. Gines P, Arroyo V, Rodes J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997;1:129–55.
147. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992;16:249–50.
148. Arroyo V, Rodes J. A rational approach to the treatment of ascites. Postgrad Med 1975;51:558–62.
149. Gines P, Arroyo V, Rodes J. Disorders of renal function in cirrhosis. In: Boyer T, Zakim D, eds. Hepatology: a textbook of liver disease. Philadelphia: BC Decker, 1996:659–64.
150. Gines P, Fernandez-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997;17:175–89.
151. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med 1970;49:175–85.
152. Schrier R. Pathogenesis of sodium and water retention in highoutput and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy, parts I-II. N Engl JMed 1988;9:1127–34.
153. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver; its relation to portal hypertension, ascites, and renal failure. J Clin Invest 1967;46:1297–308.
154. Lieberman FL, Denison EK, Reynolds TB. The relationship of volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the overflow theory of ascites formation. Ann NY Acad Sci 1970;170:202–12.
155. Anderson RJ, Cronin RE, Mc Donald KM, et al. Mechanisms of portal hypertension-induced alterations in renal hemodynamics, renal water excretion, and renin secretion. J Clin Invest 1976;58:964–70.
156. Levy M. Observation on real function and ascites formation in dogs with experimental portal cirrhosis. In: Epstein M, ed. The kidney in liver disease. New York: Elsevier, 1978:131–42.
157. Levy M, Allotey JB. Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 1978;92:560–9.
158. Levy M, Wexler MJ. Renal sodium retention and ascites formation on dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity. J Lab Clin Med 1978;91:520–36.
159. Rosoff L Jr, Zia P, Reynolds T, et al. Studies of renin and aldosterone in cirrhotic patients with ascites. Gastroenterology 1975;69:698–705.
160. Epstein M. Hepatorenal syndrome. In: Epstein M, ed. The kidney in liver disease. New York: Elsevier Biomedical, 1983:377.
161. Levy M. Pathophysiology of ascites formation. In: Epstein M, ed. The kidney in liver disease. New York: Elsevier Biomedical, 1983:245.
162. Klepetko W, Muller C, Hartter E, et al. Plasma atrial natriuretic factor in cirrhotic patients with ascites: effect of peritoneovenous shunt implantation. Gastroenterology 1988;95:764–70.
163. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity impaired sodium and water excretion in cirrhosis. N Engl J Med 1982;307:552–7.
164. Floras JS, Legault L, Morali GA, et al. Increased sympathetic outflowin cirrhosisandascites: direct evidence fromintraneural recordings. Ann Intern Med 1991;114:373–80.
165. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8: 1151–7.
166. Claria J, Jimenez W, Arroyo V, et al. Effects of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100:494–501.
167. Pariente E, Bataille C, Bercoff E, et al. Acute effects of captopril on systemic and renal hemodynamics and on renal functions in cirrhotic patients with ascites. Gastroenterology 1985;88: 1255–9.
168. Guevara M, Gines P, Fernandez-Esparrach G. Effects of normalizationof vasoconstrictor systemsonrenal functions in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:71.
169. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984;87:1120–6.
170. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359–63.
171. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite andnitrate levels in patientswith cirrhosis: relationship toendotoxemia. Hepatology 1993;18:1139–43.
172. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993;104:1750–4.
173. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235–9.
174. Battista S, Fusco B, Mengozzi G. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. Hepatology 1995;23(suppl 1):73A. 175.
175. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776–8.
176. Cattau EL Jr, Benjamin SB, Knuff TE, et al. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982;247:1164–6.
177. Dinkel E, Lehnart R, Troger J, et al. Sonographic evidence of intraperitoneal fluid: an experimental study and its clinical implications. Pediatr Radiol 1984;14:299–303.
178. Franken EJ. Ascites in infants and children: roentgen diagnosis. Radiology 1972;102:393–8.
179. Griscom NT, Colodny AH, Rosenberg HK, et al. Diagnostic aspects of neonatal ascites: report of 27 cases. Am J Roentgenol 1977;128:961–9.
180. Runyon BA, Montano AA, Akriviadis EA, et al. The serumascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215–20.
181. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988;95: 1351–5.
182. Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985;31:1–48.
183. Pokros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986;90:1827–33.
184. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998;27:264–72.
185. Fogel MR, Sawhney VK, Neal EA, et al. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981;3:73–80.
186. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983;84:961–8.
187. Gregory PB, Broekelschen PH, Hill MD, et al. Complications of diuresis in the alcoholic patient with ascites: a controlled trial. Gastroenterology 1977;73:534–8.
188. Moult PJ, Lunzer MR, Trash DB, et al. Use of bumetanide in the treatment of ascites due to liver disease. Gut 1974;15:988–92.
189. Arroyo V, Bosch J, Casamitjana R, et al. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level. Gut 1980;21:855–9.
190. Lebrec D, Hillon P, Munoz C, et al. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982;2:523–7.
191. Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287:1209–14.
192. Wilkinson SP, Bernardi M, Smith IK, et al. Effect of betaadrenergic blocking drugs on the renin-aldosterone system, sodium excretion and renal hemodynamics. Gastroenterology 1977;73:659–63.
193. Rector WG Jr, Reynolds TB. Propranolol in the treatment of cirrhotic ascites. Arch Intern Med 1984;144:1761–3.
194. Gines P, Arroyo V, Quintero E, et al. Comparison between paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987;93:234–41.
195. Pinto PC, Amerian J, Reynolds TB. Large-volume paracentesis in nonedematous patients with tense ascites: its effect on intravascular volume. Hepatology 1988;8:207–10.
196. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493–502.
197. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management patients with cirrhosis and ascites. Gastroenterology 1990;98:146–51.
198. Smart HL, Triger DR. A randomized prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. J Hepatol 1990;10:191–7.
199. Wilde JT, Cooper P, Kennedy HJ, et al. Coagulation disturbances following ascites recirculation. J Hepatol 1990;10: 217–22.
200. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995;21:986–94.
201. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192–7.
202. Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989;321:1632–8.
203. Hassall E, Benson L, Hart M, et al. Hepatic encephalopathy after portacaval shunt in a noncirrhotic child. J Pediatr 1984;105: 439–41.
204. Zaki AE, Ede RJ, Davis M, et al. Experimental studies of blood brain barrier permeability in acute hepatic failure. Hepatology 1984;4:359–63.
205. Zaki AE, Wardle EN, Canalese J, et al. Potential toxins of acute liver failure and their effects on blood–brain barrier permeability. Experientia 1983;39:988–91.
206. Roy S, Pomier-Layrargues G, Butterworth RF, et al. Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology 1988;8:845–9.
207. Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet 1997;350:1309–15.
208. Walker CO, Schenker S. Pathogenesis of hepatic encephalopathy –with special reference to the role of ammonia. Am J Clin Nutr 1970;23:619–32.
209. Nance FC, Kaufman HJ, Kline DG. Role of urea in the hyperammonemia of germ-free Eck fistula dogs. Gastroenterology 1974;66:108–12.
210. Snodgrass PJ, De Long GR. Urea-cycle enzyme deficiencies and an increased nitrogen load producing hyperammonemia in Reye’s syndrome. N Engl J Med 1976;294:855–60.
211. Bessman SP, Bradley JE. Uptake of ammonia by muscle; its implications in ammoniagenic coma. N Engl J Med 1955;253: 1143–7.
212. Uribe M, Marquez MA, Garcia Ramos G, et al. Treatment of chronic portal systemic encephalopathywith vegetable and animal protein diets: a controlled cross-over study. Dig Dis Sci 1982;27:1109–16.
213. Pappas SC, Ferenci P, Schafer DF, et al. Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and comainduced by synergistic neurotoxins. Gastroenterology 1984;86:546–51.
214. Cole M, Rutherford RB, Smith FO. Experimental ammonia encephalopathy in the primate. Arch Neurol 1972;26:130–6.
215. Mac Gillilray B. EEG monitoring in metabolic liver disease. In: Glaser G, ed. Handbook of electroencephalography and clinical neurophysiology. Vol 15:Metabolic endocrine and toxi diseases. New York: Elsevier Scientific Publishing, 1975:5–26.
216. Phear EA, Ruebner B, Sherlock S, et al. Methionine toxicity in liver disease and its prevention by chlortetracycline. Clin Sci (Lond) 1956;15:93–117.
217. Challenger F, Walshe JM. Foetor hepaticus. Lancet 1955;268: 1239–41.
218. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans andammoniaor fatty acids in the production of coma:apossible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974;83:16–28.
219. McClain CJ, Zieve L, Doizaki WM, et al. Blood methanethiol in alcoholic liver diseasewith andwithout hepatic encephalopathy. Gut 1980;21:318–23.
220. Chen S, Mahadevan V, Zieve L. Volatile fatty acids in the breath of patients with cirrhosis of the liver. J Lab Clin Med 1970;75:622–7.
221. Linscheer WG, Castell DO, Platt RR. A new method for evaluation of portasystemic shunting. The rectal octanoate tolerance test. Gastroenterology 1969;57:415–23.
222. Zieve L. Coma production with ammonia: synergistic factors. Gastroenterology 1980;78:1327A. 223.
223. Fisher JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 2;2:75–80.
224. Borg J, Warter JM, Schlienger JL, et al. Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy. J Neurol Sci 1982;57:343–56.
225. Cuilleret G, Pomier-Layrargues G, Pons F, et al. Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut 1980;21:565–9.
226. Hirayama C. Tryptophanmetabolism in liver disease. Clin Chim Acta 1971;32:191–7.
227. Record CO, Chase RA, Alberti KG, et al. Disturbances in glucose metabolism in patients with liver damage due to paracetamol overdose. Clin Sci Mol Med 1975;49:473–9.
228. Schafer DF, Fowler JM, Jones EA. Colonic bacteria: a source of gamma-aminobutyric acid in blood. Proc Soc Exp Biol Med 1981;167:301–3.
229. Schafer DF, Jones EA. Hepatic encephalopathy and the gammaaminobutyric- acid neurotransmitter system. Lancet 1982;1: 18–20.
230. Ferenci P, Covell D, Schafer DF, et al. Metabolism of the inhibitory neurotransmitter gamma-aminobutyric acid in a rabbit model of fulminant hepatic failure. Hepatology 1983; 3:507–12.
231. Ferenci P, Schafer DF, Kleinberger G, et al. Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. Lancet 1983;2:811–14.
232. Schafer DF, Fowler JM, Munson PJ, et al. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 1983;102:870–80.
233. Blitzer BL, Waggoner JG, Jones EA, et al. A model of fulminant hepatic failure in the rabbit. Gastroenterology 1978;74: 664–71.
234. Smiaowski A. The effect of intrahippocampal administration of gamma-aminobutyric acid (GABA). In. Fonnum E, ed. Amino acids as chemical transmitters. New York: Plenum Press, 1978:1977.
235. Lavoie J, Giguere JF, Layrargues GP, et al. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 1987;49:692–7.
236. Butterworth RF, Lavoie J, Giguere JF, et al. Affinities and densities of high-affinity [3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 1988;8:1084–8.
237. Record C. Neurochemistry of hepatic encephalopathy. Gut 1991;32:1261–3.
238. Baraldi M, Zeneroli ML, Ventura E, et al. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist. Clin Sci (Lond) 1984;67:167–75.
239. Olasmaa M, Guidotti A, Rothstein JD. Naturally occurring benzodiazepines in CSF of patients with hepatic encephalopathy. Sjoc Nekurosci Abs 1988;15:199.
240. Scolo-Levizzaire G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist. Lancet 1985;1:1324–5.
241. Pomier-Layrargues G, Giguere JF, Butterworth RF. Clinical trials of the efficacy of fluamzenil in hepatic coma. JHepatol 1990; 10:S13.
242. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998;13:351–60.
243. Faloon WW, Evans GL. Precipitating factors in genesis of hepatic coma. N Y State J Med 1970;70:2891–6.
244. Cadranel JF, Lebiez E, Di Martino V, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol 2001;96:515–18.
245. Watanabe A. Cerebral changes in hepatic encephalopathy. J Gastroenterol Hepatol 1998;13:752–60.
246. Kostler H. Proton magnetic resonance spectroscopy in portalsystemic encephalopathy. Metab Brain Dis 1998;13:291–301.
247. Dawson AM, Mc Laren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957;273:1262–8.
248. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatmentof acuteportal-systemic encephalopathy. A controlled, double-blind clinical trial. Am JDig Dis 1978; 23:398–406.
249. Berk DP, Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970;73:393–6.
250. Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97–105.
251. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A doubleblind clinical trial. N Engl J Med 1969;281:408–12.
252. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72(4 pt 1):573–83.
253. Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore:Williams &Wilkins, 1979:261.
254. Bircher J, Haemmerli UP, Trabert E, et al. The mechanism of action of lactulose in portal-systemic encephalopathy. Nonionic diffusion of ammonia in the canine colon. Rev Eur Etud Clin Biol 1971;16:352–7.
255. Vince A, Zeegen R, Drinkwater JE, et al. The effect of lactulose on the faecal flora of patients with hepatic encephalopathy. J Med Microbiol 1974;7:163–8.
256. Uribe M, Campollo O, Vargas F, et al. Acidifyingenemas(lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639–43.
257. Vince A, Killingley M, Wrong OM. Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 1978;74:544–9.
258. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a doubleblind, randomized trial. Hepatology 1987;7:1278–84.
259. Sabath LD, Toftegaard I. Rapid microassays for clindamycin and gentamicin when present together and the effect of p H and of each on the antibacterial activity of the other. Antimicrob Agents Chemother 1974;6:54–9.
260. Weber F. Combination therapy with lactulose and antibiotics. In: Seeff LB, Conn H, eds. Hepatic encephalopathy: management with lactulose a and related carbohydrates. East Lansing, MI: Medi Ed Press, 1988:207–17.
261. Pirotte G, Guffens JM, Devos J. Comparative study of basal arterial ammonemia of orally-induced hyperammonemia of chronic portal systemic encephalopathy, treatedwithneomycin, lactulose, and an association of neomycin and lactulose. Digestion 1974;10:435–44.
262. Eriksson LS, Persson A, Wahren J. Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 1982;23:801–6.
263. Wahren J, Denis J, Desurmont P, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983;3:475–80.
264. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984;4:279–87.
265. Cascino A, Cangiano C, Calcaterra V, et al. Plasma amino acids imbalance in patients with liver disease. Am J Dig Dis 1978; 23:591–8.
266. Rossi-Fanelli F, Freund H, Krause R, et al. Induction of coma in normal dogs by the infusion of aromatic amino acids and its prevention by the addition of branched-chain amino acids. Gastroenterology 1982;83:664–71.
267. Rossi-Fanelli F, Riggio O, Cangiano C, et al. Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Dig Dis Sci 1982;27:929–35.
268. Mc Ghee A, Henderson JM, Millikan WJ Jr, et al. Comparison of the effects of Hepatic-Aid and a Casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients. Ann Surg 1983;197:288–93.
269. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473–9.
270. Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996;20:159–64.
271. Charlton CP, Buchanan E, Holden CE, et al. Intensive enteral feeding in advanced cirrhosis: reversal of malnutrition without precipitation of hepatic encephalopathy. Arch Dis Child 1992;67:603–7.
272. Ferenci P, Grim G, Meryn S. Benzodiazepine antagonists in the treatment of human hepatic encephalopathy. In: Santiago G, ed. Cirrhosis, hepatic encephalopathy and ammonium toxicity. New York: Plenum Press, 1990:255–65.
273. Gyr K, Meier R. Flumazenil in the treatment of portal systemic encephalopathy –an overview. Intensive Care Med 1991; 17(suppl 1):S39–42.
274. Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996;16:329–38.
275. Lunzer M, James IM, Weinman J, et al. Treatment of chronic hepatic encephalopathy with levodopa. Gut 1974;15:555–61.
276. Morgan MY, Jakobovits AW, James IM, et al. Successful use of bromocriptine in the treatmentof chronic hepatic encephalopathy. Gastroenterology 1980;78:663–70.
277. Uribe M, Farca A, Marquez MA, et al. Treatment of chronic portal systemic encephalopathy with bromocriptine: a doubleblind controlled trial. Gastroenterology 1979;76:1347–51.
278. Rossle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998;18:73–89.
279. Dodds WJ, Hoyer LW. Coagulation activities in perfused organs: regulation by addition of animal plasmas. Br J Haematol 1974; 26:497–509.
280. Saito H, Hamilton SM, Tavill AS, et al. Synthesis and release of Hageman factor (Factor XII) by the isolated perfused rat liver. J Clin Invest 1983;72:948–54.
281. Deykin D, Cochios F, De Camp G, et al. Hepatic removal of activated factor X by the perfused rabbit liver. Am J Physiol 1968;214:414–19.
282. Duetsch D. Blood coagulation changes in liver disease. Prog Liver Dis 1965;2:69–83.
283. Aster R. Production, distribution, life-span, and fate of platelets. In: Beutler E, Williams WJ, eds. Hematology. New York: Mc Graw-Hill, 1977:1210.
284. Gazzard BG, Portmann B, Murray-Lyon IM, et al. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q JMed 1975;44:615–26.
285. Weston MJ, Langley PG, Rubin MH, et al. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977;18:897–902.
286. Ingeberg S, Jacobsen P, Fischer E, et al. Platelet aggregation and release of ATP in patients with hepatic cirrhosis. Scand J Gastroenterol 1985;20:285–8.
287. Owen JS, Hutton RA, Day RC, et al. Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res 1981;22:423–30.
288. O’Grady JG, Langley PG, Isola LM, et al. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 1986;6:159–63.
289. Hughes RD, Lane DA, Ireland H, et al. Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. Clin Sci (Lond) 1985;68:701–7.
290. Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982;35:667–72.
291. Soria J, Soria C, Ryckewaert JJ, et al. Study of acquired dysfibrinogenaemia in liver disease. Thromb Res 1980;19:29–41.
292. Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest 1978;61:535–8.
293. Ekindjian OG, Devanlay M, Duchassaing D, et al. Multivariate analysis of clinical and biological data in cirrhotic patients: application to prognosis. Eur J Clin Invest 1981;11:213–20.
294. Nanji AA, Blank DW. Clinical status as reflected in biochemical tests on patients with chronic alcoholic liver disease. Clin Chem 1983;29:992–3.
295. Wion KL, Kelly D, Summerfield JA, et al. Distribution of factor VIIIm RNAandantigen inhumanliverandother tissues. Nature 1985;317:726–9.
296. Kelly DA, Summerfield JA. Hemostasis in liver disease. Semin Liver Dis 1987;7:182–91.
297. Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1972;52: 679–89.
298. Verstraete M, Vermylen J, Collen D. Intravascular coagulation in liver disease. Annu Rev Med 1974;25:447–55.
299. Colman RW, Marder V, Salzman EW. Overview of hemostasis. In: Hirsh J, Colman RW, Marder VJ, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1987:3–18.
300. Carr JM. Disseminated intravascular coagulation in cirrhosis. Hepatology 1989;10:103–10.
301. Cioni G, Cristani A, Mussini C, et al. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients. Ital J Gastroenterol 1990;22:70–4.
302. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984;64:791–6.
303. Bauer KA, Bednarek M. Detection of factor X activation in humans. Thromb Haemost 1987;58:280A. 304.
304. Ho CH, Hou MC, Lin HC, et al. Can advanced hemostatic parameters detect disseminated intravascular coagulation more accurately in patients with cirrhosis of the liver? Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:332–8.
305. Tollefsen DM, Blank MK. Detection of a new heparindependent inhibitor of thrombin in humanplasma. JClin Invest 1981;68:589–96.
306. Sanders NL, Bajaj SP, Zivelin A, et al. Inhibition of tissue factors/ factor VIIa activity in plasma requires factor Xand an additional plasma component. Blood 1985;66:204–12.
307. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930–7.
308. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138–43.
309. Atkison PR, Jardine L, Williams S, et al. Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy. Transplant Proc 2005;37:1091–3.
310. Macdougall BR, Bailey RJ, Williams R. H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet 1977;1:617–19.
311. Friedman EW, Sussman II. Safety of invasive procedures in patientswith the coagulopathy of liver disease. Clin Lab Haematol 1989;11:199–204.
312. Sharma P, Mc Donald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982;4:451–3.
313. Agnelli G, Berrettini M, De Cunto M, et al. Desmopressininduced improvement of abnormal coagulation in chronic liver disease. Lancet 1983;1:645.
314. Mannuccio PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148–53.
315. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985;291:1377–81.
316. Burghard R, Leititis JU, Rossi R, et al. Treatment of severe coagulation disturbances as a condition of improved prognosis in fulminant liver failure. Arch Dis Child 1985;60:167–70.
317. Fujiwara K, Ono K, Akamatsu K, et al. Treatment with antithrombin III concentrate in fulminant hepatic failure. Hepatology 1987;7:1067A. 318.
318. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: variations on a theme. Medicine (Baltimore) 1971;50: 161–97.
319. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis. Scand J Gastroenterol 1987;22:295–300.
320. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995;3:311–28.
321. Larcher VF, Manolaki N, Vegnente A, et al. Spontaneous bacterial peritonitis in children with chronic liver disease: clinical features and etiologic factors. J Pediatr 1985;106: 907–12.
322. Rabinovitz M, Gavaler JS, Kumar S, et al. Role of serum complement, immunoglobulins, and cell-mediated immune system in the pathogenesis of spontaneous bacterial peritonitis (SBP). Dig Dis Sci 1989;34:1547–52.
323. Rimola A, Bory F, Teres J, et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5:463–7.
324. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343–6.
325. Such J, Guarner C, Enriquez J, et al. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988;6:80–4.
326. Runyon BA, Morrissey RL, Hoefs JC, Wyle FA. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985;5:634–7.
327. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997;17:203–17.
328. Ho H, Guerra LG, Zuckerman MJ. Urinary tract infection: a predisposing factor for spontaneous bacterial peritonitis. Gastroenterology 1990;98:A593.
329. Barnes PF, Arevalo C, Chan LS, et al. A prospective evaluation of bacteremic patients with chronic liver disease. Hepatology 1988;8:1099–103.
330. Leggiadro RJ, Lazar LF. Spontaneous bacterial peritonitis due to Neisseria meningitidis serogroup Z in an infant with liver failure. Clin Pediatr (Phila) 1991;30:350–2.
331. Clark JH, Fitzgerald JF, Kleiman MB. Spontaneous bacterial peritonitis. J Pediatr 1984;104:495–500.
332. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983;3:545–9.
333. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis 1998;27:669–74; quiz 675–6.
334. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171–5.
335. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986;146:2259–61.
336. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004;40: 484–8.
337. Runyon BA, Umland ET, Merlin T. Inoculation of blood culture bottles with ascitic fluid. Improved detection of spontaneous bacterial peritonitis. Arch Intern Med 1987;147:73–5.
338. Runyon BA, Antillon MR, Akriviadis EA, et al. Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990;28:2811–12.
339. Castellote J, Xiol X, Verdaguer R, et al. Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. Am J Gastroenterol 1990;85:1605–8.
340. Siersema PD, de Marie S, van Zeijl JH, et al. Blood culture bottles are superior to lysis-centrifugation tubes for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1992;30:667–9.
341. Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 1984;4: 447–50.
342. Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990;98:127–33.
343. Garrison RN, Cryer HM, Howard DA, et al. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984;199:648–55.
344. Deviere J, Content J, Crusiaux A, et al. IL-6 and TNF alpha in ascitic fluid during spontaneous bacterial peritonitis. Dig Dis Sci 1991;36:123–4.
345. Mc Hutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Owen RL, Surawica CM, eds. Gastrointestinalandhepatic infections. Philadelphia: WB Saunders, 1994:455–75.
346. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457–62.
347. Grange JD, Amiot X, Grange V, et al. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 1990;11:360–4.
348. Runyon BA, Mc Hutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100:1737–42.
349. Terg R, Cobas S, Fassio E, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of amulticenter, randomized study. J Hepatol 2000;33:564–9.
350. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996;111: 1011–17.
351. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.
352. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992;21:257–75.
353. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27–31.
354. Runyon BA, Van Epps DE. Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 1986;6:396–9.
355. Such J, Guarner C, Soriano G, et al. Selective intestinal decontamination increases serum and ascitic fluid C3 levels in cirrhosis. Hepatology 1990;12:1175–8.
356. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12 (4 pt 1):716–24.
357. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477–81.
358. Ring-Larsen H, Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 1981;22:585–91.
359. Punukollu RC, Gopalswamy N. The hepatorenal syndrome. Med Clin North Am 1990;74:933–43.
360. Kew MC, Brunt PW, Varma RR, et al. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971;2:504–10.
361. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164–76.
362. Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646–54.
363. Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005;100:460–7.
364. Kramer L, Horl WH. Hepatorenal syndrome. Semin Nephrol 2002;22:290–301.
365. Crawford DH, Endre ZH, Axelsen RA, et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992;19:339–44.
366. Iwatsuki S, Popovtzer MM, Corman JL, et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 1973;289:1155–9.
367. Gonwa TA, Morris CA, Goldstein RM, et al. Long-termsurvival and renal function following liver transplantation in patients with and without hepatorenal syndrome –experience in 300 patients. Transplantation 1991;51:428–30.
368. Koppel MH, Coburn JW, Mims MM, et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367–71.
369. Ring-Larsen H, Hesse B, Stigsby B. Effect of portal-systemic anastomosis on renal haemodynamics in cirrhosis. Gut 1976; 17:856–60.
370. Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986;70:477–84.
371. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and asciteswith andwithout functional renal failure. Gastroenterology 1989;97:1304–12.
372. Lenz K, Hortnagl H, Druml W, et al. Beneficial effect of 8- ornithine vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989;30:90–6.
373. Lenz K, Hortnagl H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991;101:1060.
374. Zipser RD, Hoefs JC, Speckart PF, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895–900.
375. Zambraski EJ, Dunn MJ. Importance of renal prostaglandins in control of renal function after chronic ligation of the common bile duct in dogs. J Lab Clin Med 1984;103:549–59.
376. Zipser RD, Radvan GH, Kronborg IJ, et al. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84:697–703.
377. Moore K, Ward PS, Taylor GW, et al. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991;100:1069–77.
378. Gupta S, Morgan TR, Gordan GS. Calcitonin gene–related peptide in hepatorenal syndrome. Apossible mediator of peripheral vasodilation? J Clin Gastroenterol 1992;14:122–6.
379. Epstein M, Goligorsky MS. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 1997;10:120–35.
380. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and treatment of the hepatorenal syndrome with ascites. Gastroenterolgoy 1993;105:229–36.
381. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999;10:1833–9.
382. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001;34:1242–51.
383. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20: 1495–501.
384. Nanji AA, Halstead AC. Spurious decrease in serum creatinine in patients with hyperbilirubinemia. Dig Dis Sci 1982;27:1051.
385. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987;82:945–52.
386. Rudman D, Di Fulco TJ, Galambos JT, et al. Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects. J Clin Invest 1973;52:2241–9.
387. Bernardi M, De Palma R, Trevisani F, et al. Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide. Hepatology 1986;6:400–5.
388. Simon DM, McCain JR, Bonkovsky HL, et al. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 1987;7:423–9.
389. Epstein M. Hepatorenal syndrome. In: Epstein M, ed. The kidney in liver disease. Baltimore: Williams & Wilkins, 1988:89–97.
390. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. JClin Invest 1967;46:1894–906.
391. Golper TA. Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 1985;6:373–86.
392. Kaplan AA, Longnecker RE, Folkert VW. Continuous arteriovenous hemofiltration. A report of six months’ experience. Ann Intern Med 1984;100:358–67.
393. Alarabi AA, Danielson BG, Wikstrom B, et al. Artificial renal and liver support in a severe hepatorenal syndrome of childhood. Acta Paediatr 1992;81:75–8.
394. Schroeder ET, Anderson GH Jr, Smulyan H. Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 1979;15:54–61.
395. Linas SL, Schaefer JW, Moore EE, et al. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986;30:736–40.
396. Pladson TR, Parrish RM. Hepatorenal syndrome. Recovery after peritoneovenous shunt. Arch Intern Med 1977;137:1248–9.
397. Gillam GL, Stokes KB, Mc Lellan J, et al. Fulminant hepatic failure with intractable ascites due to an echovirus 11 infection successfully managed with a peritoneo-venous (Le Veen) shunt. J Pediatr Gastroenterol Nutr 1986;5:476–80.
398. Brensing KA, Textor J, Strunk H, et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697–8.
399. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with cirrhosis. Am J Gastroenterol 2005;100:879–85.
400. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690.
401. Pomier-Layragues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebocontrolled, crossover study. Hepatology 2003;100:879.
402. Arieff AI, Chidsey CA. Renal function in cirrhosis and the effects of prostaglandin A. Am J Med 1974;56:695–703.
403. Zusman RM, Axelrod L, Tolkoff-Rubin N. The treatment of the hepatorenal syndrome with intra-renal administration of prostaglandin E1. Prostaglandins 1977;13:819–30.
404. Fevery J, Van Cutsem E, Nevens F, et al. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990;11:153–8.
405. Zipser RD, Kronborg I, Rector W, et al. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 1984;87:1228–32.
406. Pinzani M, Laffi G, Meacci E, et al. Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology 1988;95:1081–7.
407. Polson RJ, Park GR, Lindop MJ, et al. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987;42:15–19.
408. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122: 1658–76.
409. Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Arch Intern Med 1993;153:1957–63.
410. Seu P, Wilkinson AH, Shaked A, et al. The hepatorenal syndrome in liver transplant recipients. Am Surg 1991;57:806–9.
411. Nielsen K, Kondrup J, Martinsen L, et al. Long-termoral refeeding of patients with cirrhosis of the liver. Br J Nutr 1995;74: 557–67.
412. Nielsen K, Kondrup J, Martinsen L, et al. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993;69:665–79.
413. Greco AV, Mingrone G, Benedetti G, et al. Daily energy and substrate metabolism in patients with cirrhosis. Hepatology 1998;27:346–50.
414. Muller MJ, Fenk A, Lautz HU, et al. Energy expenditure and substrate metabolism in ethanol-induced liver cirrhosis. Am J Physiol 1991;260(3 pt 1):E338–44.
415. Cabre E, Gassull MA. Nutritional issues in cirrhosis and liver transplantation. Nutrition in chronic liver disease and liver transplantation. Curr Opin Clin Nutr Metab Care 1999;2: 373–80.
416. Swart GR, Zillikens MC, van Vuure JK, et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989;299:1202–3.
417. Verboeket-van de Venne WP, Westerterp KR, van Hoek B, et al. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake. Gut 1995;36:110–16.
418. Yamanaka H, Genjida K, Yokota K, et al. Daily pattern of energy metabolism in cirrhosis. Nutrition 1999;15:749–54.
419. Cabre E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990;98:715–20.
420. Hirsch S, de la Maza MP, Gattas V, et al. Nutritional support in alcoholic cirrhotic patients improves host defenses. J Am Coll Nutr 1999;18:434–41.
421. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patientswith chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993; 233:385–92.
422. Aleynik SI, Leo MA, Ma X, et al. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol 1997;27: 554–61.
423. Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr 1997;127:1800–6.
424. Ma X, Zhao J, Lieber CS. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 1996;24:604–13.
425. Poniachik J, Baraona E, Zhao J, et al. Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J Lab Clin Med 1999;133:342–8.
426. Lochs H, Plauth M. Liver cirrhosis: rationale and modalities for nutritional support –the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 1999;2:345–9.
427. Protheroe SM. Feeding the child with chronic liver disease. Nutrition 1998;14:796–800.